Antiviral stockpiles for influenza pandemics from the household perspective: Treatment alone versus treatment with prophylaxis

被引:1
|
作者
Kwok, Kin On [1 ,2 ]
Leung, Gabriel M. [1 ,2 ]
Mak, Peter [1 ,2 ]
Riley, Steven [1 ,2 ,3 ]
机构
[1] Univ Hong Kong, Dept Community Med, Pokfulam, Hong Kong, Peoples R China
[2] Univ Hong Kong, Sch Publ Hlth, Pokfulam, Hong Kong, Peoples R China
[3] Univ London Imperial Coll Sci Technol & Med, MRC Ctr Outbreak Anal & Modelling, Dept Infect Dis Epidemiol, Sch Publ Hlth, London SW7 2AZ, England
基金
英国惠康基金; 美国国家卫生研究院;
关键词
Pandemic influenza (pandemic flu); Treatment; Prophylaxis; Antiviral drugs; Mathematical models; UNITED-STATES; A H1N1; VIRUS; TRANSMISSION; STRATEGIES; OUTBREAK;
D O I
10.1016/j.epidem.2012.11.001
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Model-based studies of antiviral use to mitigate the impact of moderate and severe influenza pandemics implicitly take the viewpoint of a central public health authority. However, it seems likely that the key decision of when to use antivirals will be made at the household level. We used a stochastic compartmental model of the transmission of influenza within and between households to evaluate the expected mortality under two strategies: households saving available antivirals for treatment only and households implementing prophylaxis as well as treatment. Given that every individual in the population was allocated a single course of antivirals, we investigated the impact of these two strategies for a wide range of AVE(D), the efficacy of antivirals in preventing death in severe cases (AVE(D) = 1 for complete protection). We found a cross-over point for our baseline parameter values in a regime where antivirals were still highly effective in reducing the chance of death: below AVE(D) = 0.9 the optimal strategy was for households to use both treatment and prophylaxis. We also considered the possibility that a small number of households might "cheat" by choosing to follow the treatment-only strategy when other households were following treatment with prophylaxis. The cross-over point for cheating households was considerably lower, at AVE(D) = 0.6, but substantially above 0. These results suggest that unless antivirals are almost completely effective in reducing the chance of death in serious cases, households will likely be better served implementing prophylaxis as well as treatment. More generally, our study illustrates the potential value of considering viewpoints other than a central authority when conducting model-based analysis of interventions against infectious disease. (C) 2013 Elsevier B. V. All rights reserved.
引用
收藏
页码:92 / 97
页数:6
相关论文
共 50 条
  • [21] The treatment of influenza with antiviral drugs
    Stiver, G
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2003, 168 (01) : 49 - 57
  • [22] Influenza: prevention, prophylaxis and treatment
    Jones, S.
    Jones, R.
    SOUTH AFRICAN FAMILY PRACTICE, 2008, 50 (02) : 38 - 41
  • [23] A remote household-based approach to influenza self-testing and antiviral treatment
    Heimonen, Jessica
    McCulloch, Denise J.
    O'Hanlon, Jessica
    Kim, Ashley E.
    Emanuels, Anne
    Wilcox, Naomi
    Brandstetter, Elisabeth
    Stewart, Mark
    McCune, David
    Fry, Scott
    Parsons, Sean
    Hughes, James P.
    Jackson, Michael L.
    Uyeki, Timothy M.
    Boeckh, Michael
    Starita, Lea M.
    Bedford, Trevor
    Englund, Janet A.
    Chu, Helen Y.
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2021, 15 (04) : 469 - 477
  • [24] Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective
    Carrasco, Luis R.
    Lee, Vernon J.
    Chen, Mark I.
    Matchar, David B.
    Thompson, James P.
    Cook, Alex R.
    JOURNAL OF THE ROYAL SOCIETY INTERFACE, 2011, 8 (62) : 1307 - 1313
  • [25] A model for influenza with vaccination and antiviral treatment
    Arino, Julien
    Brauer, Fred
    van den Driessche, P.
    Watmough, James
    Wu, Jianhong
    JOURNAL OF THEORETICAL BIOLOGY, 2008, 253 (01) : 118 - 130
  • [26] Antiviral Drugs for the Treatment and Prevention of Influenza
    Rubaiyea Farrukee
    Aeron C. Hurt
    Current Treatment Options in Infectious Diseases, 2017, 9 (3) : 318 - 332
  • [27] Investigational antiviral therapies for the treatment of influenza
    Yang, Jie
    Huang, Yingna
    Liu, Shuwen
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (05) : 481 - 488
  • [28] Influenza Antiviral Treatment and Length of Stay
    Campbell, Angela P.
    Tokars, Jerome I.
    Reynolds, Sue
    Garg, Shikha
    Kirley, Pam Daily
    Miller, Lisa
    Yousey-Hindes, Kimberly
    Anderson, Evan J.
    Oni, Oluwakemi
    Monroe, Maya
    Kim, Sue
    Lynfield, Ruth
    Smelser, Chad
    Muse, Alison T.
    Felsen, Christina
    Billing, Laurie M.
    Thomas, Ann
    Mermel, Elizabeth
    Lindegren, Mary Lou
    Schaffner, William
    Price, Andrea
    Fry, Alicia M.
    PEDIATRICS, 2021, 148 (04)
  • [29] Antiviral treatment of influenza in South Korea
    Choe, Young June
    Lee, Hyunju
    Lee, Hoan Jong
    Choi, Eun Hwa
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2015, 13 (06) : 741 - 749
  • [30] Antiviral treatment of childhood influenza: an update
    Moodley, Amaran
    Bradley, John S.
    Kimberlin, David W.
    CURRENT OPINION IN PEDIATRICS, 2018, 30 (03) : 438 - 447